Sm08502-onc-01

Author: fwul

August undefined, 2024

Webb29 sep. 2024 · add_box. SAN DIEGO, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering … WebbORG STUDY ID : SM08502-ONC-01 NCT ID : NCT03355066 Conditions Solid Tumor, Adult Interventions Purpose This study is an open-label, multi-center, dose-escalation, dose …

Epic Sciences And Biosplice Therapeutics Announce Partnership …

http://www.usalifesciences.com/us/portal/news_details.php?news_id=28606851k$SnKVXke2weSNs Webb13 dec. 2024 · SM08502 inhibited cell viability in all 14 cell lines (regardless of KRAS status) (EC 50 =0.072-0.526 μM). In Capan-1, HPAFII, and Panc1 cells, 1 μM SM08502 … open in play store app什么意思

The CLK inhibitor SM08502 induces anti-tumor activity

Webb27 jan. 2024 · As part of this relationship, Biosplice will leverage Epic’s comprehensive platform to characterize drug activity and patient response in Biosplice’s SM08502-ONC … Webb6 jan. 2024 · Mel J. Yeates. SAN DIEGO—In late 2024, Samumed, LLC noted the publication of data demonstrating a novel mechanism of action for SM08502 in preclinical … Webb[VIRTUAL] SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt pathway inhibition in castration-resistant prostate … ipad add to home screen

SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor ...

Webb31 mars 2024 · In an iterative screening campaign of >1500 compounds, SM08502 was developed as a small-molecule CLK inhibitor with IC 50 values of 0.002 μM for CLK2 and … Webb20 okt. 2024 · Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced CRPC. Subjects will receive increasing doses of SM08502 with fixed doses of … open inp file in abaqusWebbAs part of this relationship, Biosplice will leverage Epic's comprehensive platform to characterize drug activity and patient response in Biosplice's SM08502-ONC-01 and SM08502-ONC-03 trials. "We are excited to partner with Epic in our biomarker development program" states Darrin Beaupre , MD, PhD, Chief Medical Officer, Oncology at Biosplice … open in portuguese

"WebbThe study will evaluate the safety, tolerability, PK, PD, and preliminary anti-tumor efficacy of SM08502 administered orally, once daily, following a 28-day treatment cycle (Part 1A). … " - Sm08502-onc-01

Sm08502-onc-01

WO2024023840A1 - Novel tumor-specific antigens for cancer …

WebbSM08502, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects as Monotherapy and in … WebbCancer stem cells (CSCs) are a subpopulation of tumor cells that can drive tumor initiation and can cause relapses. These cells are seen as drivers of tumor establishment and growth, often correlated to aggressive, heterogeneous and therapy-resistant tumors. Novel tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) specifically …

Did you know?

Webb27 jan. 2024 · Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and … WebbThis study is an open-label, multi-center, dose-escalation, dose-finding and expansion study in adult subjects with advanced solid tumors for whom no standard therapy is available. …

Webb27 jan. 2024 · As part of this relationship, Biosplice will leverage Epic's comprehensive platform to characterize drug activity and patient response in Biosplice's SM08502-ONC-01 and SM08502-ONC-03 trials. "We are excited to partner with Epic in our biomarker development program" states Darrin Beaupre , MD, PhD, Chief Medical Officer, Oncology … Webb6 apr. 2024 · SM08502 (cirtuvivint) is a novel pan CDC-like kinase (CLK) and Dual specificity tyrosine kinase (DYRK) inhibitor that targets mRNA splicing and is optimized …

Webb1 aug. 2024 · HEC265, SNGM, and Ishikawa-S33Y tumors all had significantly lower tumor volumes with combination of SM08502 and paclitaxel compared to single-agent … WebbSM08502-ONC-01: A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects with …

Webb15 aug. 2024 · Abstract. Dysregulation of the cyclin D-CDK4/6-RB signaling axis is implicated in HR+ breast cancer (BC). While CDK4/6 inhibitors such as palbociclib …

Webb27 jan. 2024 · SAN DIEGO, Jan. 27, 2024 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK … ipad aesthetic png ipad aed cu-sp1WebbApply to this Phase 1 clinical trial treating Non-small Cell Lung Cancer, Colorectal Carcinoma (CRC), Castration-resistant Prostate Cancer. Get access to cutting edge … open in private window internet explorerWebbCirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research [1] . Cirtuvivint (SM08502) inhibits … ipad affirmWebb17 nov. 2024 · Drug: SM08502. SM08502 tablets to be administered orally. Arms, Groups and Cohorts. Experimental: Part 1A: Dose Escalation. Cohorts of subjects with advanced … ipad affirm financingWebb27 jan. 2024 · SAN DIEGO, Jan. 27, 2024 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK … open inprivate by defaultWebbOmipalisib C25H17F2N5O3S CID 25167777 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities ... open in private window chrome